CFP and glomerulonephritis: We showed that, in the absence of properdin, glomerulonephritis was less severe and progressed more slowly—disease activity markers were lower at the 4 month endpoint, which included autoantibody levels, inflammatory cytokines, complement activation, and tissue damage (Figure 4).